WeTrials
Recruiting

LuCa-MERIT-1: First-in-human, Open Label, Phase I Dose Confirmation Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer

What is this study?

This early-stage clinical trial is testing a new immunotherapy treatment called BNT116, both on its own and mixed with other standard cancer drugs, for people with a common type of lung cancer. The main goal is to find out if these treatments are safe and what the best dose is to help patients.

Who can participate?

Adults with non-small cell lung cancer that is advanced, has spread, or cannot be removed by surgery may be eligible to join. Certain groups have specific requirements depending on their cancer stage and genetic traits.

What will happen?

Participants will receive the study treatment, which could be BNT116 alone or combined with other therapies like chemotherapy or targeted drugs, while doctors closely monitor their health and safety.

Where and when?

This study is currently recruiting patients at select locations in the United States, including sites in Kentucky and Maryland.

Key Points
  • 1Testing a new lung cancer immunotherapy called BNT116
  • 2Study looks at safety and the best dosage for patients
  • 3Open to individuals with advanced or specific stages of lung cancer

No related links yet

Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Non-Small Cell Lung Cancer

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.